BMO Capital Downgrades Ionis Pharmaceuticals to Market Perform, Lowers Price Target to $60
BMO Capital Downgrades Ionis Pharmaceuticals to Market Perform, Lowers Price Target to $60
BMO Capital將Ionis Pharmaceuticals的評級下調至市場表現，將目標價降至60美元
BMO Capital analyst Kostas Biliouris downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Market Perform and lowers the price target from $67 to $60.
BMO資本分析師Kostas Biliouris將Ionis Pharmaceuticals（納斯達克：IONS）評級從Outperform下調至Market Perform，並將價格目標從67美元下調至60美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。